Phase II Studies of Two Different Schedules of Dasatinib (NSC-732517) in Bone Metastasis Predominant Metastatic Breast Cancer.
Phase of Trial: Phase II
Latest Information Update: 11 Jan 2019
At a glance
- Drugs Dasatinib (Primary)
- Indications Advanced breast cancer; Bone metastases
- Focus Biomarker; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 31 May 2017 Status changed from active, no longer recruiting to completed.
- 22 May 2013 Planned end date changed from 1 Nov 2011 to 1 Sep 2013 as reported by ClinicalTrials.gov.